Received October 24, 2019
Accepted April 27, 2020

The transgender men are individuals who identify as men but were assigned female sex at birth. Gender-affirming medications include testosterone hormone therapy, which has diverse effects throughout the body, including an atrophic effect on the endometrium and inducing amenorrhea by suppressing ovulation, without affecting the ovarian follicle pool. Our aim is to report the first Brazilian case involving a transgender man and his cisgender woman partner who wanted to build a family. A 34-year-old transgender man and his partner, a 28-year-old woman were admitted in our assisted reproduction service. He had a history of 2 years testosterone use. At their initial consultation testosterone was discontinued. A controlled ovarian stimulation for the transgender man was achieved using a combination of recombinant gonadotropins FSH and LH. Pituitary blockage was performed using a GnRH antagonist protocol. Twenty follicles were aspirated and 16 oocytes were retrieved, specifically 12 mature oocytes, which were inseminated with a semen donor sample. On the fifth day of development, one high quality blastocyst was transferred to cisgender woman partner, resulting in an ongoing pregnancy. Five supernumerary embryos were cryopreserved. Controlled ovarian stimulation with high quality oocytes, high quality embryos and clinical pregnancies is feasible for transgender men, even with a history of testosterone use.